病毒与淋巴瘤

doi:10.3760/cma.j.issn.1673-422X.2014.02.015

摘要/Abstract

摘要： 病毒感染是导致机体发生淋巴瘤的主要病因之一。研究发现爱泼斯坦巴尔病毒(EBV)、人免疫缺陷病毒(HIV)、丙型肝炎病毒(HCV)和乙型肝炎病毒(HBV)等均是通过不同途径及机制感染机体，导致淋巴瘤的发生发展。对于病毒感染所致淋巴瘤的研究将有利于阐明淋巴瘤发生的分子机制，并对进一步探索有效的治疗方案具有重要意义。

关键词: 爱泼斯坦巴尔病毒感染, HIV, 肝炎病毒属, 肝炎病毒, 乙型, 淋巴瘤

Abstract: Virus infection is a major cause of lymphoma. Research shows that EpsteinBarr virus, human immunodeficiency virus, hepatitis C virus and hepatitis B virus involve in the occurrence and development of lymphoma through different ways and mechanisms. It is important significance that viral infection research elucidates the molecular mechanisms of lymphoma and explores therapy ways.

Key words: EpsteinBarr virus infections, HIV, Hepacivirus, Hepatitis B virus, Lymphoma

吴遐, 汪运生, 邓芳. 病毒与淋巴瘤[J]. 国际肿瘤学杂志, 2014, 41(2): 127-130.

Wu Xia, Wang Yunsheng, Deng Fang. Virus and malignant lymphoma[J]. Journal of International Oncology, 2014, 41(2): 127-130.

参考文献

［1］ Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and nonHodgkin lymphomas: a review of the epidemiological evidence［J］. J Intern Med, 2008, 264(6): 537-548. ［2］ Wu ZZ, Chow KP, Kuo TC, et al. Latent membrane protein 1 of EpsteinBarr virus sensitizes cancer cells to cisplatin by enhancing NFκB p50 homodimer formation and downregulating NAPA expression［J］. Biochem Pharmacol, 2011, 82(12): 1860-1872. ［3］ Lu J, Murakami M, Verma SC, et al. EpsteinBarr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBVpositive Blymphoma cells through upregulation of survivin［J］. Virology, 2011, 410(1): 64-75. ［4］ Muromoto R, Ikeda O, Okabe K, et al. EpsteinBarr virusderived EBNA2 regulates STAT3 activation［J］. Biochem Biophys Res Commun, 2009, 378(3): 439-443. ［5］ Staudt LM. Ⅱ. Therapy of DLBCL based on genomics［J］. Hematol Oncol, 2013, 1: 26-28. ［6］ Souza EM, Baiocchi OC, Zanichelli MA, et al. Impact of EpsteinBarr virus in the clinical evolution of patients with classical Hodgkin′s lymphoma in Brazil［J］. Hematol Oncol, 2010, 28(3): 137-141. ［7］ Lima RT, Seca H, Soares P, et al. EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide［J］. J Cell Biochem, 2011, 112(1): 200-210. ［8］ Cheng W, Li YM, Yang DJ, et al. Effect of gossypol acetate on proliferation and apoptosis in Raji lymphoblastoid cell line［J］. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2009, 31(5): 527-532. ［9］ Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of EpsteinBarr virusDNA in plasma and peripheral blood mononuclear cells of extranodal NK/Tcell lymphoma, nasal type［J］. Blood, 2011, 118(23): 6018-6022. ［10］ Ian MX, Lan SZ, Cheng ZF, et al. Suppression of EBNA1 expression inhibits growth of EBVpositive NK/T cell lymphoma cells［J］. Cancer Biol Ther, 2008, 7(10): 1602-1606. ［11］ Omar H, Hgglund H, GustafssonJernberg A, et al. Targeted monitoring of patients at high risk of posttransplant lymphoproliferative disease by quantitative EpsteinBarr virus polymerase chain reaction［J］. Transpl Infect Dis, 2009, 11(5): 393-399. ［12］ Peric Z, Cahu X, Chevallier P, et al. Features of EpsteinBarr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation［J］. Leukemia, 2011, 25(6): 932-938. ［13］ Peric Z, Cahu X, Chevallier P, et al. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation［J］. Bone Marrow Transplant, 2012, 47(2): 251-257. ［14］ Toulza F, Nosaka K, Takiguchi M, et al. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV1associated adult Tcell leukemia［J］. Int J Cancer, 2009, 125(10): 2375-2382. ［15］ Kozako T, Yoshimitsu M, Fujiwara H, et al. PD1/PDL1 expression in human Tcell leukemia virus type 1 carriers and adult Tcell leukemia/lymphoma patients［J］. Leukemia, 2009, 23(2): 375-382. ［16］ Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDSrelated lymphoma［J］. J Clin Oncol, 2010, 28(5): 773-779. ［17］ Wiggill TM, Mantina H, Willem P, et al. Changing pattern of lymphoma subgroups at a tertiary academic complex in a highprevalence HIV setting: a South African perspective［J］. J Acquir Immune Defic Syndr, 2011, 56(5): 460-466. ［18］ Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of nonAIDSdefining cancers in people with HIV infection［J］. J Clin Oncol, 2009, 27(6): 884-890. ［19］ Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early and lateHAART periods: the Swiss HIV Cohort Study［J］. Br J Cancer, 2010, 103(3): 416-422. ［20］ Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors［J］. J Immunol, 2012, 188(1): 497-503. ［21］ Tussiwand R, Rauch M, Flück LA, et al. BAFFR expression correlates with positive selection of immature B cells［J］. Eur J Immunol, 2012, 42(1): 206-216. ［22］ Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferonalpha, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a longterm study［J］. Blood, 2010, 116(3): 343-353. ［23］ Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa2b plus ribavirin for HCVpositive mixed cryoglobulinemia: a multicentre openlabel study［J］. Clin Exp Rheumatol, 2011, 29(6): 933-941. ［24］ HartridgeLambert SK, Stein EM, Markowitz AJ, et al. Hepatitis C and nonHodgkin lymphoma: the clinical perspective［J］. Hepatology, 2012, 55(2): 634-641. ［25］ Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virusassociated mixed cryoglobulinemia contain an expanded anergic CD21low Bcell subset［J］. Blood, 2011, 117(20): 5425-5437. ［26］ Martyak LA, Yeganeh M, Saab S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to nonHodgkin′s lymphoma［J］. Clinl Gastroenterol Hepatol, 2009, 7(8): 900-905. ［27］ Becker N, Fortuny J, Alvaro T, et al. Medical history and risk of lymphoma: results of a European casecontrol study (EPILYMPH)［J］. J Cancer Res Clin Oncol, 2009, 135(8): 1099-1107. ［28］ Marcucci F, Mele A. Hepatitis viruses and nonHodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities［J］. Blood, 2011, 117(6): 1792-1798. ［29］ Nath A, Agarwal R, Malhotra P, et al. Prevalence of hepatitis B virus infection in nonHodgkin lymphoma: a systematic review and metaanalysis［J］. Intern Med J, 2010, 40(9): 633-641. ［30］ Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of nonHodgkin lymphoma in South Korea: a cohort study［J］. Lancet Oncol, 2010, 11(9): 827-834. ［31］ Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell nonHodgkin′s lymphoma［J］. Ann Hematol, 2008, 87(6): 475-480.

[1]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[2]	殷运燕, 李慧, 李雨晨, 惠慧, 许景艳. 组蛋白去乙酰化酶抑制剂在非霍奇金淋巴瘤中的临床应用[J]. 国际肿瘤学杂志, 2022, 49(8): 499-504.
[3]	王柳雪, 席晓平, 刘静静, 沈国民, 杨海平. 二甲双胍在非霍奇金淋巴瘤中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 436-440.
[4]	孙淑琴, 钱秋红, 张友忠. 盆腔原发弥漫性大B细胞淋巴瘤1例[J]. 国际肿瘤学杂志, 2022, 49(5): 319-320.
[5]	郭奕维, 刘爱春. EB病毒阳性弥漫大B细胞淋巴瘤的治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 385-388.
[6]	李巧佴, 邹立群. 老年弥漫大B细胞淋巴瘤的分层治疗策略[J]. 国际肿瘤学杂志, 2021, 48(5): 317-320.
[7]	乔薇, 宋腾, 陈馨蕊, 王华庆. PI3K信号通路过度激活对非霍奇金淋巴瘤患者预后的影响及其靶向药物疗效[J]. 国际肿瘤学杂志, 2021, 48(2): 121-124.
[8]	陈丽娜, 郭智, 刘玄勇, 陈晓, 张弋慧智, 李旭绵, 韦丽娅, 王月乔, 谢晶. EAC动员方案在淋巴瘤自体造血干细胞移植中的应用研究[J]. 国际肿瘤学杂志, 2021, 48(11): 666-672.
[9]	许蕾, 戴婧, 张倩, 张文丽, 李晋萌, 张红宇. 93例成人急性淋巴细胞白血病的临床分析[J]. 国际肿瘤学杂志, 2020, 47(9): 535-541.
[10]	杨蕾, 张传玉, 张在先, 刘欢. 非小细胞肺癌影像基因组学[J]. 国际肿瘤学杂志, 2020, 47(9): 555-559.
[11]	赵可, 王华庆. 复发/难治外周T细胞淋巴瘤的新药治疗进展[J]. 国际肿瘤学杂志, 2020, 47(6): 321-326.
[12]	王才华, 赵有红, 丰翠, 林照, 杨涟, 葛卫星. 深部软组织弥漫大B细胞淋巴瘤一例[J]. 国际肿瘤学杂志, 2020, 47(5): 319-320.
[13]	齐菲, 董梅. 原发上呼吸消化道外结外NK/T细胞淋巴瘤的临床特征及生存分析[J]. 国际肿瘤学杂志, 2020, 47(3): 157-163.
[14]	柴玥, 董梅. 淋巴瘤凝血异常机制及预后评估作用[J]. 国际肿瘤学杂志, 2020, 47(10): 637-640.
[15]	国建林, 张传玉, 于华龙, 张在先. 影像基因组学在肺癌中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(9): 544-547.